Charles River Laboratories Stock (CRL)

XNYS Alert Compare

Health Care · Fundamental analysis

Charles River Laboratories's revenue has grown by 6.5% a year over the last 5 years – slower than the median of the Health Care sector (+8.5%). The last fiscal year ended with a net loss (net margin −3.6%, sector median 13.9%). The 52-week high is 20.8% away (close of Nov 20, 2026).

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

1 strength · 3 weaknesses · Fiscal year to Dec 27, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 3 of 7 criteria with data met · 1 without data
  • Growth 2 of 7 criteria with data met
  • Dividend 0 of 1 criteria with data met · 6 without data
  • Financial strength 5 of 6 criteria with data met
Chart position more than 10% above – position relative to the 200-day line

Strengths well above the threshold

  • Equity ratio 44.4% Threshold: above 30% · Distance +14.4 pp · Sector median 44.2% (63 stocks) · Fiscal year to Dec 27, 2025

Weaknesses well below the threshold

  • Net margin −3.6% Threshold: above 10% · Distance −13.6 pp · Sector median 12.9% (63 stocks) · Fiscal year to Dec 27, 2025
  • Return on equity −4.6% Threshold: above 15% · Distance −19.6 pp · Sector median 12.8% (54 stocks) · Fiscal year to Dec 27, 2025
  • Profitable years 4 of 5 Threshold: 5 of 5 · Fiscal year to Dec 27, 2025

On the radar

  • Position relative to the 200-day line: more than 10% above (as of Nov 20, 2026)
  • Free cash flow margin 12.9% – Threshold: above 10%, distance +2.9 pp (Fiscal year to Dec 27, 2025)
  • Revenue growth 5 years +6.5% per year – Threshold: above 5% per year, distance +1.5 pp (Fiscal year to Dec 27, 2025)

What we do not know

  • Data missing: 1 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 27, 2025).
    • Gross margin above 40%

Not applicable

  • Pays no dividend – the dividend criteria do not apply (Fiscal year to Dec 27, 2025).

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Charles River Laboratories is a service provider for pharmaceutical and biotech companies. It conducts preclinical safety studies for new drug candidates, supplies research animals and offers testing services for drug manufacturing. As of Oct 11, 2026

Fact sheet (from the annual report) Contract research (biology and medicine) · Wilmington, USA

Charles River Laboratories sees itself as a partner for non-clinical drug development, having grown out of laboratory animal medicine. Its offering ranges from research models and drug discovery to safety testing under GLP and non-GLP conditions. The Manufacturing Solutions segment comprises Microbial Solutions for microbial quality control and Biologics Solutions for testing biologic drugs. This includes endotoxin tests for injectable products and medical devices based on an extract from horseshoe crabs. Its customers include pharmaceutical companies, biotech firms, contract research and contract manufacturing organizations, hospitals, universities and government agencies.

Automatically summarized from SEC annual report (10-K, filed Feb 18, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Charles River Laboratories

This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today −4.2%
  • 7 days −7.0%
  • 30 days −8.9%
  • 1 year +93.9%
Day range (last trading day)
−1.2%Price at 23% of the range+4.1%
52-week range
−53.5%Price at 72% of the range+20.8%
Distance from the all-time high
−31.7%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles up
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • higher highs and higher lows

    Price above the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles not available

    No value on 4 hours (too few or no checked 4-hour candles).

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
stronger
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX between 20 and 25 – a moderate trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility high Typical daily range (ATR 14) above 4% of the price – high.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran stronger.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 6 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
6 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
8 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 6 of 10 years
  • February: higher in 7 of 10 years
  • March: higher in 5 of 10 years
  • April: higher in 2 of 10 years
  • May: higher in 7 of 10 years
  • June: higher in 7 of 10 years
  • July: higher in 7 of 10 years
  • August: higher in 4 of 10 years
  • September: higher in 4 of 10 years
  • October: higher in 6 of 10 years
  • November (current month): higher in 6 of 10 years
  • December: higher in 7 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January6 of 10
February7 of 10
March5 of 10
April2 of 10
May7 of 10
June7 of 10
July7 of 10
August4 of 10
September4 of 10
October6 of 10
November ●6 of 10
December7 of 10

Through October 2026 (last completed month) · from our daily candles

Fundamental analysis

Charles River Laboratories · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 18, 2026.

One-off effect in profit – prior-year figures are only partly comparable. unusually high profit in quarter Q3/26 (net margin 33.9%).

For you first Dividend

The company pays no dividend.

For you first Valuation

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
2 of 7
criteria with data met
Revenue per year (5 y)
+6.5%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
3 of 7
criteria with data met
Net margin
−3.6%
Return on equity
−4.6%

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
up
daily candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 27, 2025

Quality 3 of 7 met · 1 without data

  • no data: Gross margin above 40% not stated in the SEC filings
  • not met: Operating margin above 15% 0.6%
  • not met: Net margin above 10% −3.6%
  • not met: Return on equity above 15% −4.6%
  • met: Free cash flow margin above 10% 12.9%
  • not met: Profit in each of the last 5 fiscal years 4 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 44.4%
Operating margin

0.6% Fiscal year 2025

Rank 17 of 100: higher than 17% of 470 peers (All). weak.

Rank 12 of 100: higher than 12% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

−3.6% Fiscal year 2025

Rank 10 of 100: higher than 10% of 584 peers (All). weak.

Rank 9 of 100: higher than 9% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

−4.6% Fiscal year 2025

Rank 10 of 100: higher than 10% of 544 peers (All). weak.

Rank 10 of 100: higher than 10% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

−2.0% Fiscal year 2025 (total assets at year end)

Rank 10 of 100: higher than 10% of 594 peers (All). weak.

Rank 10 of 100: higher than 10% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

44.4% Fiscal year 2025

Rank 62 of 100: higher than 62% of 595 peers (All). medium.

Rank 52 of 100: higher than 52% of 63 peers (Sector). medium.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

12.9% Fiscal year 2025

Rank 54 of 100: higher than 54% of 465 peers (All). medium.

Rank 42 of 100: higher than 42% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

518.5M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 2 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +0.3%
  • met: Over 5 years, revenue grew by more than 5% per year +6.5%
  • met: Over 10 years, revenue grew by more than 5% per year +11.4%
  • not met: Over 3 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Over 5 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 3 of 5
  • not met: Revenue rose in the last fiscal year −0.9%
Revenue growth 3 years

+0.3% per year

Rank 22 of 100: higher than 22% of 578 peers (All). weak.

Rank 20 of 100: higher than 20% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+6.5% per year

Rank 37 of 100: higher than 37% of 549 peers (All). medium.

Rank 39 of 100: higher than 39% of 60 peers (Sector). medium.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+11.4% per year

Rank 77 of 100: higher than 77% of 412 peers (All). strong.

Rank 73 of 100: higher than 73% of 50 peers (Sector). strong.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 3 of 7 · 2 without data
  • met: Long-term debt no higher than equity 0.68
  • met: Current assets cover current liabilities 1.29
  • met: Positive equity 3.2B USD
  • met: In 5 years, share count up by at most 5% −2.1%
  • met: Free cash flow positive in the last fiscal year 518.5M USD
Piotroski F-Score

3 of 7 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.68 at fiscal year end

Rank 47 of 100: lower than 47% of 486 peers (All). medium.

Rank 45 of 100: lower than 45% of 50 peers (Sector). medium.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.29 at fiscal year end

Rank 48 of 100: higher than 48% of 513 peers (All). medium.

Rank 33 of 100: higher than 33% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−2.1% in 5 years

Rank 46 of 100: lower than 46% of 507 peers (All). medium.

Rank 40 of 100: lower than 40% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • not met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • no data: No additional shares (diluted share count did not rise)
  • no data: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+6.5% per year), more slowly than the sector median.
  • Light red: Loss in the last fiscal year.
  • Light yellow: Debt higher than usual in the sector.
  • Light yellow: Profit in 9 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Dec 27, 2015 – Dec 31, 2016): Revenue 1.7B USD · Net income 154.8M USD · Net margin 9.2%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 30, 2017): Revenue 1.9B USD · Net income 123.4M USD · Net margin 6.6%
  3. Fiscal year 2018 (Dec 31, 2017 – Dec 29, 2018): Revenue 2.3B USD · Net income 226.4M USD · Net margin 10.0%
  4. Fiscal year 2019 (Dec 30, 2018 – Dec 28, 2019): Revenue 2.6B USD · Net income 252.0M USD · Net margin 9.6%
  5. Fiscal year 2020 (Dec 29, 2019 – Dec 26, 2020): Revenue 2.9B USD · Net income 364.3M USD · Net margin 12.5%
  6. Fiscal year 2021 (Dec 27, 2020 – Dec 25, 2021): Revenue 3.5B USD · Net income 391.0M USD · Net margin 11.0%
  7. Fiscal year 2022 (Dec 26, 2021 – Dec 31, 2022): Revenue 4.0B USD · Net income 486.2M USD · Net margin 12.2%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 30, 2023): Revenue 4.1B USD · Net income 474.6M USD · Net margin 11.5%
  9. Fiscal year 2024 (Dec 31, 2023 – Dec 28, 2024): Revenue 4.0B USD · Net income 22.2M USD · Net margin 0.5%
  10. Fiscal year 2025 (Dec 29, 2024 – Dec 27, 2025): Revenue 4.0B USD · Net income −144.3M USD · Net margin −3.6%

Fiscal year 2025 (Dec 29, 2024 – Dec 27, 2025): Revenue 4.0B USD · Net income −144.3M USD · Net margin −3.6%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 −2.2% vs. the same quarter a year earlier.

Revenue 12 months vs. prior 12
−1.2%
12 months: 4.0B USD · Fiscal year 2025: −0.9%
Net margin 12 months
1.0%
Fiscal year 2025: −3.6%
Free cash flow margin 12 months
10.0%
Fiscal year 2025: 12.9%
More depth

Calculation of the 12 months to Sep 26, 2026

  • Revenue: fiscal year to Dec 27, 2025 4.0B USD + year to date to Sep 26, 2026 3.0B USD − same period a year earlier to Sep 27, 2025 3.0B USD = 4.0B USD
  • Net income: fiscal year to Dec 27, 2025 −144.3M USD + year to date to Sep 26, 2026 316.7M USD − same period a year earlier to Sep 27, 2025 132.2M USD = 40.2M USD
  • Operating cash flow: fiscal year to Dec 27, 2025 737.6M USD + year to date to Sep 26, 2026 474.9M USD − same period a year earlier to Sep 27, 2025 590.1M USD = 622.4M USD
  • Capital expenditure: fiscal year to Dec 27, 2025 219.2M USD + year to date to Sep 26, 2026 133.8M USD − same period a year earlier to Sep 27, 2025 130.2M USD = 222.8M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 26982.7M−2.2%333.1M33.9%
Apr–Jun 261.0B−2.7%−1.5M−0.1%
Jan–Mar 26995.8M+1.2%−14.8M−1.5%
Oct–Dec 25*994.2M−0.8%−276.6M−27.8%
Jul–Sep 251.0B−0.5%54.4M5.4%
Apr–Jun 251.0B+0.6%52.3M5.1%
Jan–Mar 25984.2M−2.7%25.5M2.6%
Oct–Dec 24*1.0B−1.1%−214.5M−21.4%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 26, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

There was no profit in fiscal year 2025; interest is thinly covered.

Cash flow ÷ profit
–
no profit in fiscal year 2025
Interest coverage
0.2x
well covered from 5 · 3 years: 2.4x
Tax rate
–
no profit before tax · 3 years: 36.8%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 737.6M USD ÷ group profit incl. minority interests −142.2M USD = no ratio (no profit)
  • Operating income 25.2M USD ÷ Interest expense 107.0M USD = 0.2x
  • Taxes 42.7M USD ÷ profit before tax −99.5M USD = no rate (no profit before tax)
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
2025–0.2x–
2024over 10x1.8x72.8%
20231.42x4.5x17.4%
20221.26x11.0x20.9%
20211.91x8.0x17.0%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years one loss year and 2 years with lower revenue.

Loss years
1 of 10
net income below zero
Years with lower revenue
2 of 10
revenue below the prior year
Net margin range
16.1 percentage points
from −3.6% to 12.5%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025−0.9%−3.6%
2024−1.9%0.5%
2023+3.9%11.5%
2022+12.3%12.2%
2021+21.1%11.0%
2020+11.5%12.5%
2019+15.7%9.6%
2018+22.0%10.0%
2017+10.5%6.6%
2016+23.3%9.2%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 0.6 USD operating income remained.

Net loss: −3.6% of revenue

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue4.0B USD100.0%
Operating income25.2M USD0.6%
Cost of revenue and operating expenses4.0B USD99.4%
Taxes, interest & other169.5M USD4.2%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 14.8% to 0.6%.

Operating marginNet margin
  1. Fiscal year 2016: Operating margin 14.1% · Net margin 9.2%
  2. Fiscal year 2017: Operating margin 15.5% · Net margin 6.6%
  3. Fiscal year 2018: Operating margin 14.6% · Net margin 10.0%
  4. Fiscal year 2019: Operating margin 13.4% · Net margin 9.6%
  5. Fiscal year 2020: Operating margin 14.8% · Net margin 12.5%
  6. Fiscal year 2021: Operating margin 16.7% · Net margin 11.0%
  7. Fiscal year 2022: Operating margin 16.4% · Net margin 12.2%
  8. Fiscal year 2023: Operating margin 14.9% · Net margin 11.5%
  9. Fiscal year 2024: Operating margin 5.6% · Net margin 0.5%
  10. Fiscal year 2025: Operating margin 0.6% · Net margin −3.6%

Returns

Return on equity fell in 5 years from 17.2% to −4.6%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 18.5% · Return on assets 5.7%
  2. Fiscal year 2017: Return on equity 11.8% · Return on assets 4.2%
  3. Fiscal year 2018: Return on equity 17.2% · Return on assets 5.9%
  4. Fiscal year 2019: Return on equity 15.4% · Return on assets 5.4%
  5. Fiscal year 2020: Return on equity 17.2% · Return on assets 6.6%
  6. Fiscal year 2021: Return on equity 15.4% · Return on assets 5.6%
  7. Fiscal year 2022: Return on equity 16.3% · Return on assets 6.4%
  8. Fiscal year 2023: Return on equity 13.2% · Return on assets 5.8%
  9. Fiscal year 2024: Return on equity 0.6% · Return on assets 0.3%
  10. Fiscal year 2025: Return on equity −4.6% · Return on assets −2.0%

Equity and long-term debt

The equity ratio rose in 5 years from 38.5% to 44.4%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 836.8M USD · Long-term debt 1.2B USD
  2. Fiscal year 2017: Equity 1.0B USD · Long-term debt 1.1B USD
  3. Fiscal year 2018: Equity 1.3B USD · Long-term debt 1.6B USD
  4. Fiscal year 2019: Equity 1.6B USD · Long-term debt 1.8B USD
  5. Fiscal year 2020: Equity 2.1B USD · Long-term debt 1.9B USD
  6. Fiscal year 2021: Equity 2.5B USD · Long-term debt 2.7B USD
  7. Fiscal year 2022: Equity 3.0B USD · Long-term debt 2.7B USD
  8. Fiscal year 2023: Equity 3.6B USD · Long-term debt 2.6B USD
  9. Fiscal year 2024: Equity 3.5B USD · Long-term debt 2.2B USD
  10. Fiscal year 2025: Equity 3.2B USD · Long-term debt 2.1B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.43 to 1.29.

Current ratio
  1. Fiscal year 2016: Current ratio 1.53
  2. Fiscal year 2017: Current ratio 1.78
  3. Fiscal year 2018: Current ratio 1.61
  4. Fiscal year 2019: Current ratio 1.44
  5. Fiscal year 2020: Current ratio 1.43
  6. Fiscal year 2021: Current ratio 1.23
  7. Fiscal year 2022: Current ratio 1.32
  8. Fiscal year 2023: Current ratio 1.52
  9. Fiscal year 2024: Current ratio 1.41
  10. Fiscal year 2025: Current ratio 1.29

Cash flow

Free cash flow rose in 5 years from 380.0M USD to 518.5M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 316.9M USD · Capital expenditure 55.3M USD · Free cash flow 261.6M USD
  2. Fiscal year 2017: Operating cash flow 318.1M USD · Capital expenditure 82.4M USD · Free cash flow 235.6M USD
  3. Fiscal year 2018: Operating cash flow 441.1M USD · Capital expenditure 140.1M USD · Free cash flow 301.1M USD
  4. Fiscal year 2019: Operating cash flow 480.9M USD · Capital expenditure 140.5M USD · Free cash flow 340.4M USD
  5. Fiscal year 2020: Operating cash flow 546.6M USD · Capital expenditure 166.6M USD · Free cash flow 380.0M USD
  6. Fiscal year 2021: Operating cash flow 760.8M USD · Capital expenditure 228.8M USD · Free cash flow 532.0M USD
  7. Fiscal year 2022: Operating cash flow 619.6M USD · Capital expenditure 324.7M USD · Free cash flow 294.9M USD
  8. Fiscal year 2023: Operating cash flow 683.9M USD · Capital expenditure 318.5M USD · Free cash flow 365.4M USD
  9. Fiscal year 2024: Operating cash flow 734.6M USD · Capital expenditure 233.0M USD · Free cash flow 501.6M USD
  10. Fiscal year 2025: Operating cash flow 737.6M USD · Capital expenditure 219.2M USD · Free cash flow 518.5M USD

Share count

The share count fell in 5 years by 2.1% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 48.0M
  2. Fiscal year 2017: Diluted share count 48.6M
  3. Fiscal year 2018: Diluted share count 49.0M
  4. Fiscal year 2019: Diluted share count 49.7M
  5. Fiscal year 2020: Diluted share count 50.6M
  6. Fiscal year 2021: Diluted share count 51.4M
  7. Fiscal year 2022: Diluted share count 51.3M
  8. Fiscal year 2023: Diluted share count 51.5M
  9. Fiscal year 2024: Diluted share count not available
  10. Fiscal year 2025: Diluted share count 49.6M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Earnings per share

Earnings per share fell in 5 years from 7.20 USD to −2.91 USD.

CRL USD per share
  1. Fiscal year 2016: CRL 3.23 USD
  2. Fiscal year 2017: CRL 2.54 USD
  3. Fiscal year 2018: CRL 4.62 USD
  4. Fiscal year 2019: CRL 5.07 USD
  5. Fiscal year 2020: CRL 7.20 USD
  6. Fiscal year 2021: CRL 7.60 USD
  7. Fiscal year 2022: CRL 9.48 USD
  8. Fiscal year 2023: CRL 9.22 USD
  9. Fiscal year 2024: CRL 0.20 USD
  10. Fiscal year 2025: CRL −2.91 USD

Revenue

Revenue rose in 5 years from 2.9B USD to 4.0B USD.

CRL in USD
  1. Fiscal year 2016: CRL 1.7B USD
  2. Fiscal year 2017: CRL 1.9B USD
  3. Fiscal year 2018: CRL 2.3B USD
  4. Fiscal year 2019: CRL 2.6B USD
  5. Fiscal year 2020: CRL 2.9B USD
  6. Fiscal year 2021: CRL 3.5B USD
  7. Fiscal year 2022: CRL 4.0B USD
  8. Fiscal year 2023: CRL 4.1B USD
  9. Fiscal year 2024: CRL 4.0B USD
  10. Fiscal year 2025: CRL 4.0B USD

Net margin

The net margin fell in 5 years from 12.5% to −3.6%.

CRL Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: CRL 9.2%
  2. Fiscal year 2017: CRL 6.6%
  3. Fiscal year 2018: CRL 10.0%
  4. Fiscal year 2019: CRL 9.6%
  5. Fiscal year 2020: CRL 12.5%
  6. Fiscal year 2021: CRL 11.0%
  7. Fiscal year 2022: CRL 12.2%
  8. Fiscal year 2023: CRL 11.5%
  9. Fiscal year 2024: CRL 0.5%
  10. Fiscal year 2025: CRL −3.6% · Sector today 13.2%

Source: SEC filings, fiscal years up to Dec 27, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (5 years)
583.4M USD 100% through repurchases
Share count over 5 years
−2.1% fewer shares – each share is a larger stake

What goes back to shareholders

Over 5 years, 583.4M USD went back to shareholders, 100% of it through share repurchases. That is 26% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 12.3M USD · New shares issued (including employee plans) not available · Free cash flow 261.6M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 106.9M USD · New shares issued (including employee plans) not available · Free cash flow 235.6M USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 13.8M USD · New shares issued (including employee plans) not available · Free cash flow 301.1M USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 18.1M USD · New shares issued (including employee plans) not available · Free cash flow 340.4M USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 24.0M USD · New shares issued (including employee plans) not available · Free cash flow 380.0M USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 40.7M USD · New shares issued (including employee plans) not available · Free cash flow 532.0M USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 38.7M USD · New shares issued (including employee plans) not available · Free cash flow 294.9M USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 24.2M USD · New shares issued (including employee plans) not available · Free cash flow 365.4M USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 119.2M USD · New shares issued (including employee plans) not available · Free cash flow 501.6M USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 360.7M USD · New shares issued (including employee plans) not available · Free cash flow 518.5M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Charles River Laboratories next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison CRL, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
CRL Charles River Laboratories this stock 4.0B USD +6.5%–0.6%−3.6%−4.6%44.4%12.9%–
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
Median of the sector 27 symbols 44.3B USD +8.4%67.6%17.8%13.2%13.6%38.5%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector CRL next to MRNA – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+6.5% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 6.5% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light red: Loss

−3.6% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue there was no profit but a loss of 3.59 USD. Five years ago the margin was 12.5%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.76 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.76 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light yellow: 1 loss year

9 of 10 fiscal years with a profit

What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
4.0B USD
Revenue vs. prior year
−0.9%
Net income (FY)
−144.3M USD
Net income vs. prior year
−750.1%
EPS (FY)
-2.91 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 27, 2025 · 10-K filed Feb 18, 2026 · Balance sheet Sep 26, 2026 (filed Nov 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 27, 2025 4.0B−144.3M −3.6% −2.91 – –
2024Dec 28, 2024 4.0B22.2M 0.5% 0.20 – –
2023Dec 30, 2023 4.1B474.6M 11.5% 9.22 – –
2022Dec 31, 2022 4.0B486.2M 12.2% 9.48 – –
2021Dec 25, 2021 3.5B391.0M 11.0% 7.60 – –
2020Dec 26, 2020 2.9B364.3M 12.5% 7.20 – –
2019Dec 28, 2019 2.6B252.0M 9.6% 5.07 – –
2018Dec 29, 2018 2.3B226.4M 10.0% 4.62 – –
2017Dec 30, 2017 1.9B123.4M 6.6% 2.54 – –
2016Dec 31, 2016 1.7B154.8M 9.2% 3.23 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 26, 2026 982.7M333.1M 33.9% 6.86 – –
Q2/26Jun 27, 2026 1.0B−1.5M −0.1% −0.03 – –
Q1/26Mar 28, 2026 995.8M−14.8M −1.5% −0.30 – –
Q4/25*Dec 27, 2025 994.2M−276.6M −27.8% – – –
Q3/25Sep 27, 2025 1.0B54.4M 5.4% 1.10 – –
Q2/25Jun 28, 2025 1.0B52.3M 5.1% 1.06 – –
Q1/25Mar 29, 2025 984.2M25.5M 2.6% 0.50 – –
Q4/24*Dec 28, 2024 1.0B−214.5M −21.4% – – –
Q3/24Sep 28, 2024 1.0B69.7M 6.9% 1.33 – –
Q2/24Jun 29, 2024 1.0B94.1M 9.2% 1.74 – –
Q1/24Mar 30, 2024 1.0B73.0M 7.2% 1.30 – –
Q4/23*Dec 30, 2023 1.0B187.1M 18.5% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $3.0K1 person $19.5M2 people −$19.5M
6 months $3.0K1 person $52.1M6 people −$52.1M
12 months $7.3K2 people $52.1M6 people −$52.1M

Latest transactions

  • Oct 22, 2026 Foster James C Director Open-market sale · 10b5-1 plan 24,042 shares · $8.4M · SEC
  • Oct 21, 2026 Parisotto Shannon M Officer Open-market sale · 10b5-1 plan 2,156 shares · $742.5K · SEC
  • Oct 5, 2026 Parisotto Shannon M Officer Open-market sale · 10b5-1 plan 981 shares · $302.6K · SEC
  • Sep 30, 2026 Coleman Glenn Chief financial officer (CFO) Open-market purchase 10 shares · $3.0K · SEC
  • Aug 25, 2026 Foster James C Director Open-market sale · 10b5-1 plan 33,561 shares · $10.1M · SEC
  • Aug 19, 2026 Parisotto Shannon M Officer Open-market sale · 10b5-1 plan 2,039 shares · $599.7K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Charles River Laboratories?

All superinvestor portfolios

2 of 26 tracked superinvestors report a position.

Superinvestors with a position in Charles River Laboratories, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates < 0.1% new Q3 2026
Paul Tudor Jones Tudor Investment Corp < 0.1% new Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on CRL yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: CRL

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close